MS patients may receive less frequent rituximab infusions without increasing their chances of relapse or disease progression, ...

The following is a summary of “Rituximab combined with intravenous immunoglobulin in autoimmune diseases: a systematic review ...

A 2012 study of patients with low-tumor-burden follicular lymphoma showed that the 4-year freedom from treatment failure rate ...

For patients transitioning from rituximab to ravulizumab, meningococcal vaccination can be safely done within 6 months after ...

利妥昔单抗（Rituximab）作为首个获批的抗肿瘤单抗药物，通过靶向CD20抗原显著改善了非霍奇金淋巴瘤患者的预后。将FITC与该单抗结合，不仅保留了其免疫识别能力，更赋予实时成像功能，为肿瘤靶向治疗提供可视化导航。 标记技术优化 FITC通过其异硫氰酸基团 ...

A new study published in the journal of BMC Nephrology revealed rituximab to be an effective and safe steroid sparing medication in individuals with steroid dependent (SD)/frequent relapsing (FR) ...

AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been recommended for approval in the European Union (EU) for the treatment of adult patients with previously ...

People with multiple sclerosis (MS) may receive less frequent infusions of rituximab without increasing their chances of relapse or disease progression, according to a real-world study from Norway.

EMA committee recommends approval of AstraZeneca’s Calquence plus chemoimmunotherapy to treat adult patients with mantle cell lymphoma: Cambridge, UK Tuesday, April 1, 2025, 17: ...

netvision.net.il Objective: To assess the effect of rituximab on the efficacy and safety of influenza virus vaccine in patients with rheumatoid arthritis (RA). Methods: The study group comprised ...

med.uni-heidelberg.de In the following case series, we present four patients with different connective tissue diseases (CTD) showing a remarkably positive response on treatment with Obinutuzumab ...